Selpercatinib is under clinical development by Loxo Oncology and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Selpercatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Selpercatinib overview
Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is formulated as hard gelatin capsules for the oral route of administration. It is indicated in the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) following prior treatment with immunotherapy and/or platinum-based chemotherapy, adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib and with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) and who require systemic therapy following prior treatment with sorafenib and/or lenvatinib.
Selpercatinib (LOXO-292) is under development for the treatment of Medullary thyroid cancer, non-small cell lung cancer, anaplastic thyroid cancer, follicular thyroid cancer, papillary thyroid cancer, solid tumors including primary central nervous system tumors, pancreatic cancer, breast cancer, ovarian, small intestine cancer, Carcinoid tumor , salivary gland tumor and lung cancer. The drug candidate is administered through oral route. The drug candidate acts by targeting RET receptor tyrosine kinase.
Loxo Oncology overview
Loxo Oncology is a bio pharmaceutical company that carries out the development of targeted small molecule therapeutics for the treatment of cancer. The company’s lead product candidate includes LOXO-195, an inhibitor of tropomyosin receptor kinase (TRK), used for the treatment of solid tumor types such as neuroblastoma and lung, thyroid and breast cancers; LOXO-292, an inhibitor of Rearranged during Transfection (RET) tyrosine kinase used for the treatment of lung, thyroid, breast and colon cancers; and LOXO-305, a reversible BTK inhibitor. It is also developing a pipeline of additional product candidates targeting cancers driven by genetic alterations. Loxo Oncology is headquartered in Stamford, Connecticut, the US.
For a complete picture of Selpercatinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
